Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin + Chemotherapy in Elderly AML
NCT00052299Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2002
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Started Sep 2002; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00052299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052299.